The scientific and medical study of cannabis has come a long way in the U.S. over the past couple of decades, but despite the leaps and bounds made to regulations in many states, and the research done so far, there are still major hurdles in the industry. One of those biggest hurdles is that cannabis remains federally illegal.
As such, the DEA is able to put a stop to a lot of cannabis research, even when it is purely for medical or informational value. Dr. Lyle Craker of the University of Massachusetts—Amherst is sick of this, and is now joining forces with the Multidisciplinary Association for Psychedelic Studies (MAPS) to sue the DEA due to delays approving his research.
Craker is upset because it has been almost 20 years since he has filed to be able to study pharmaceutical cannabis in order to develop a product that is safe for patients. In the opinion of himself and MAPS, this is too long to reasonably wait, and he is taking the issue to Massachusetts state court.
“The strawman of United Nations sanctions has been removed along with all other legitimate objections,” says Allen Hopper, Esq., who is representing Craker. “With this
Bud Digest[otw_is sidebar=otw-sidebar-8]